{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T08:51:02Z","timestamp":1782982262081,"version":"3.54.5"},"reference-count":105,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.ejpb.2015.05.001","type":"journal-article","created":{"date-parts":[[2015,5,29]],"date-time":"2015-05-29T09:25:33Z","timestamp":1432891533000},"page":"323-330","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"PB","title":["Nanoengineering of therapeutics for retinal vascular disease"],"prefix":"10.1016","volume":"95","author":[{"given":"Nivriti","family":"Gahlaut","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Suarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md. Imam","family":"Uddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew Y.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie M.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwath","family":"Jayagopal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 2","key":"10.1016\/j.ejpb.2015.05.001_b0005","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1038\/eye.2012.32","article-title":"Management of retinal vascular diseases: a patient-centric approach","volume":"26","author":"Brand","year":"2012","journal-title":"Eye"},{"key":"10.1016\/j.ejpb.2015.05.001_b0010","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.preteyeres.2008.05.001","article-title":"Vascular endothelial growth factor in eye disease","volume":"27","author":"Penn","year":"2008","journal-title":"Prog. Retinal Eye Res."},{"key":"10.1016\/j.ejpb.2015.05.001_b0015","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1056\/NEJMcp1003934","article-title":"Clinical practice. Retinal-vein occlusion","volume":"363","author":"Wong","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejpb.2015.05.001_b0020","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ajpath.2012.06.006","article-title":"A brief history of anti-VEGF for the treatment of ocular angiogenesis","volume":"181","author":"Kim","year":"2012","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ejpb.2015.05.001_b0025","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejpb.2015.05.001_b0030","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nnano.2007.387","article-title":"Nanocarriers as an emerging platform for cancer therapy","volume":"2","author":"Peer","year":"2007","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.ejpb.2015.05.001_b0035","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.urolonc.2007.03.017","article-title":"New frontiers in nanotechnology for cancer treatment","volume":"26","author":"Alexis","year":"2008","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.ejpb.2015.05.001_b0040","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s11883-010-0106-7","article-title":"Insights into atherosclerosis using nanotechnology","volume":"12","author":"Jayagopal","year":"2010","journal-title":"Curr. Ather. Rep."},{"key":"10.1016\/j.ejpb.2015.05.001_b0045","doi-asserted-by":"crossref","first-page":"8288","DOI":"10.3390\/ijms12118288","article-title":"Nanotechnology and nanotoxicology in retinopathy","volume":"12","author":"Jo","year":"2011","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejpb.2015.05.001_b0050","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3129\/i10-090","article-title":"Nanotechnology in ophthalmology","volume":"45","author":"Zarbin","year":"2010","journal-title":"Can. J. Ophthalmol."},{"key":"10.1016\/j.ejpb.2015.05.001_b0055","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.drudis.2007.10.021","article-title":"Nanotechnology in ocular drug delivery","volume":"13","author":"Sahoo","year":"2008","journal-title":"Drug Discovery Today"},{"key":"10.1016\/j.ejpb.2015.05.001_b0060","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3389\/fphar.2012.00188","article-title":"Ocular drug delivery: a clue from nanotechnology","volume":"3","author":"Bucolo","year":"2012","journal-title":"Front Pharmacol."},{"key":"10.1016\/j.ejpb.2015.05.001_b0065","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1161\/01.ATV.0000201069.47550.8b","article-title":"Applications of nanotechnology to atherosclerosis, thrombosis, and vascular biology","volume":"26","author":"Wickline","year":"2006","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ejpb.2015.05.001_b0070","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1161\/01.CIR.0000059651.17045.77","article-title":"Nanotechnology for molecular imaging and targeted therapy","volume":"107","author":"Wickline","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ejpb.2015.05.001_b0075","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1021\/nn900002m","article-title":"Impact of nanotechnology on drug delivery","volume":"3","author":"Farokhzad","year":"2009","journal-title":"ACS Nano"},{"key":"10.1016\/j.ejpb.2015.05.001_b0080","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.biomaterials.2006.09.047","article-title":"Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery","volume":"28","author":"Cheng","year":"2007","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2015.05.001_b0085","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1109\/TNB.2008.2000147","article-title":"Functionalized solid lipid nanoparticles for transendothelial delivery","volume":"7","author":"Jayagopal","year":"2008","journal-title":"IEEE Trans. Nanobiosci."},{"key":"10.1016\/j.ejpb.2015.05.001_b0090","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.addr.2008.02.013","article-title":"Clinical developments in drug delivery nanotechnology","volume":"60","author":"Forrest","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2015.05.001_b0095","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.copbio.2005.10.009","article-title":"Nanotechnology for drug and gene therapy: the importance of understanding molecular mechanisms of delivery","volume":"16","author":"Labhasetwar","year":"2005","journal-title":"Curr. Opin. Biotechnol."},{"issue":"Suppl 1","key":"10.1016\/j.ejpb.2015.05.001_b0100","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.2337\/diacare.26.2007.S99","article-title":"American diabetes, diabetic retinopathy","volume":"26","author":"Fong","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejpb.2015.05.001_b0105","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1001\/archopht.122.4.552","article-title":"Eye diseases prevalence research, the prevalence of diabetic retinopathy among adults in the United States","volume":"122","author":"Kempen","year":"2004","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.ejpb.2015.05.001_b0110","doi-asserted-by":"crossref","first-page":"416","DOI":"10.4093\/dmj.2014.38.6.416","article-title":"Current concepts in diabetic retinopathy","volume":"38","author":"Song","year":"2014","journal-title":"Diab. Metab. J."},{"key":"10.1016\/j.ejpb.2015.05.001_b0115","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.preteyeres.2011.05.002","article-title":"Inflammation in diabetic retinopathy","volume":"30","author":"Tang","year":"2011","journal-title":"Prog. Retinal Eye Res."},{"key":"10.1016\/j.ejpb.2015.05.001_b0120","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/978-1-60761-150-9_7","article-title":"Mechanisms of blood\u2013retinal barrier breakdown in diabetic retinopathy","author":"Moghadam","year":"2012","journal-title":"Ophthalmol. Res. Visual Dysfunct. Diabetes"},{"key":"10.1016\/j.ejpb.2015.05.001_b0125","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s10456-007-9067-z","article-title":"Vascular permeability in ocular disease and the role of tight junctions","volume":"10","author":"Erickson","year":"2007","journal-title":"Angiogenesis"},{"key":"10.1016\/j.ejpb.2015.05.001_b0130","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.2337\/db09-1421","article-title":"Calcium dobesilate inhibits the alterations in tight junction proteins and leukocyte adhesion to retinal endothelial cells induced by diabetes","volume":"59","author":"Leal","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.ejpb.2015.05.001_b0135","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.2337\/diacare.26.9.2653","article-title":"Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies","volume":"26","author":"Ciulla","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejpb.2015.05.001_b0140","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMra1005073","article-title":"Diabetic retinopathy","volume":"366","author":"Antonetti","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejpb.2015.05.001_b0145","doi-asserted-by":"crossref","first-page":"4","DOI":"10.4103\/0974-9233.92110","article-title":"Diabetic macular edema: current and emerging therapies","volume":"19","author":"Wenick","year":"2012","journal-title":"Middle East Afr. J. Ophthalmol."},{"key":"10.1016\/j.ejpb.2015.05.001_b0150","first-page":"289","article-title":"Pain and accuracy of focal laser treatment for diabetic macular edema using a retinal navigated laser (Navilas\u00ae)","volume":"6","author":"Cheuteu","year":"2012","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.ejpb.2015.05.001_b0155","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1034\/j.1600-0420.2001.790502.x","article-title":"The therapeutic effects of retinal laser treatment and vitrectomy. A theory based on oxygen and vascular physiology","volume":"79","author":"Stefansson","year":"2001","journal-title":"Acta Ophthalmol. Scand."},{"key":"10.1016\/j.ejpb.2015.05.001_b0160","article-title":"Study of clinical applications and safety for Pascal((R)) laser photocoagulation in retinal vascular disorders","author":"Muqit","year":"2010","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.ejpb.2015.05.001_b0165","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2174\/157339906775473671","article-title":"Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy","volume":"2","author":"Simo","year":"2006","journal-title":"Curr. Diabetes Rev."},{"issue":"Suppl. 1","key":"10.1016\/j.ejpb.2015.05.001_b0170","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000315152","article-title":"The multifactorial nature of retinal vascular disease","volume":"224","author":"Kleinman","year":"2010","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.ejpb.2015.05.001_b0175","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2147\/OPTH.S27859","article-title":"Pain and accuracy of focal laser treatment for diabetic macular edema using a retinal navigated laser (Navilas)","volume":"6","author":"Kernt","year":"2012","journal-title":"Clin Ophthalmol."},{"key":"10.1016\/j.ejpb.2015.05.001_b0180","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1007\/s00125-008-0989-9","article-title":"Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy","volume":"51","author":"Simo","year":"2008","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejpb.2015.05.001_b0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/09273940701246314","article-title":"Are intravitreal anti-VEGF antibodies safe?","volume":"15","author":"Tezel","year":"2007","journal-title":"Ocul. Immunol. Inflamm."},{"key":"10.1016\/j.ejpb.2015.05.001_b0190","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.pneurobio.2011.05.011","article-title":"Age related macular degeneration and drusen: neuroinflammation in the retina","volume":"95","author":"Buschini","year":"2011","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.ejpb.2015.05.001_b0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.preteyeres.2008.10.001","article-title":"Molecular pathology of age-related macular degeneration","volume":"28","author":"Ding","year":"2009","journal-title":"Prog. Retinal Eye Res."},{"key":"10.1016\/j.ejpb.2015.05.001_b0200","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/wnan.167","article-title":"Regenerative nanomedicine and the treatment of degenerative retinal diseases, Wiley interdisciplinary reviews","volume":"4","author":"Zarbin","year":"2012","journal-title":"Nanomed. Nanobiotech."},{"key":"10.1016\/j.ejpb.2015.05.001_b0205","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/eye.2010.196","article-title":"The role of anti-inflammatory agents in age-related macular degeneration (AMD) treatment","volume":"25","author":"Wang","year":"2011","journal-title":"Eye"},{"key":"10.1016\/j.ejpb.2015.05.001_b0210","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1755-3768.2011.02295.x","article-title":"Complement system activation and endothelial dysfunction in patients with age-related macular degeneration (AMD): possible relationship between AMD and atherosclerosis","volume":"90","author":"Machalinska","year":"2012","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.ejpb.2015.05.001_b0215","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/j.ophtha.2008.02.028","article-title":"Complications of age-related macular degeneration prevention trial research, characteristics of choroidal neovascularization in the complications of age-related macular degeneration prevention trial","volume":"115","author":"Maguire","year":"2008","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ejpb.2015.05.001_b0220","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.ajo.2007.06.039","article-title":"Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients","volume":"144","author":"Brown","year":"2007","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.ejpb.2015.05.001_b0225","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1097\/IAE.0b013e3181a2c1c3","article-title":"Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration","volume":"29","author":"Forooghian","year":"2009","journal-title":"Retina"},{"key":"10.1016\/j.ejpb.2015.05.001_b0230","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1111\/j.1755-3768.2009.01773.x","article-title":"Investigation of the role of neutralizing antibodies against bevacizumab as mediators of tachyphylaxis","volume":"89","author":"Forooghian","year":"2011","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.ejpb.2015.05.001_b0235","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1016\/j.ophtha.2008.07.007","article-title":"Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration?","volume":"115","author":"Schaal","year":"2008","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ejpb.2015.05.001_b0240","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ophtha.2009.07.017","article-title":"International eye disease, the prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia","volume":"117","author":"Rogers","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ejpb.2015.05.001_b0245","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/j.1445-5994.2008.01720.x","article-title":"Retinal vein occlusion: an approach to diagnosis, systemic risk factors and management","volume":"38","author":"Yau","year":"2008","journal-title":"Int. Med. J."},{"key":"10.1016\/j.ejpb.2015.05.001_b0250","first-page":"1043","article-title":"Critical appraisal of the clinical utility of the dexamethasone intravitreal implant (Ozurdex) for the treatment of macular edema related to branch retinal vein occlusion or central retinal vein occlusion","volume":"5","author":"Chan","year":"2011","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.ejpb.2015.05.001_b0255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bjophthalmol-2011-301236","article-title":"Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance?","volume":"96","author":"Binder","year":"2012","journal-title":"Brit. J. Ophthalmol."},{"key":"10.1016\/j.ejpb.2015.05.001_b0260","doi-asserted-by":"crossref","first-page":"4676","DOI":"10.1021\/mp400487f","article-title":"Nanoparticles in porous microparticles prepared by supercritical infusion and pressure quench technology for sustained delivery of bevacizumab","volume":"10","author":"Yandrapu","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2015.05.001_b0265","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1021\/mp300716t","article-title":"Light-activated, in situ forming gel for sustained suprachoroidal delivery of bevacizumab","volume":"10","author":"Tyagi","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2015.05.001_b0270","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.jconrel.2013.09.016","article-title":"Self-assembled phenylalanine-alpha, beta-dehydrophenylalanine nanotubes for sustained intravitreal delivery of a multi-targeted tyrosine kinase inhibitor","volume":"172","author":"Panda","year":"2013","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"key":"10.1016\/j.ejpb.2015.05.001_b0275","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jconrel.2009.10.031","article-title":"Nanoparticle-integrin antagonist C16Y peptide treatment of choroidal neovascularization in rats","volume":"142","author":"Kim","year":"2010","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"key":"10.1016\/j.ejpb.2015.05.001_b0280","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1021\/nn305958y","article-title":"Targeted intraceptor nanoparticle therapy reduces angiogenesis and fibrosis in primate and murine macular degeneration","volume":"7","author":"Luo","year":"2013","journal-title":"ACS Nano"},{"key":"10.1016\/j.ejpb.2015.05.001_b0285","doi-asserted-by":"crossref","first-page":"9764","DOI":"10.1073\/pnas.93.18.9764","article-title":"Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases","volume":"93","author":"Friedlander","year":"1996","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejpb.2015.05.001_b0290","doi-asserted-by":"crossref","first-page":"e3554","DOI":"10.1371\/journal.pone.0003554","article-title":"Endogenous VEGF is required for visual function: evidence for a survival role on muller cells and photoreceptors","volume":"3","author":"Saint-Geniez","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.ejpb.2015.05.001_b0295","doi-asserted-by":"crossref","first-page":"18751","DOI":"10.1073\/pnas.0905010106","article-title":"An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris","volume":"106","author":"Saint-Geniez","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejpb.2015.05.001_b0300","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1167\/iovs.11-9139","article-title":"Nanoparticle-mediated delivery of shRNA. VEGF-a plasmids regresses corneal neovascularization","volume":"53","author":"Qazi","year":"2012","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejpb.2015.05.001_b0305","doi-asserted-by":"crossref","first-page":"4789","DOI":"10.1167\/iovs.10-5891","article-title":"A lipid nanoparticle system improves siRNA efficacy in RPE cells and a laser-induced murine CNV model","volume":"52","author":"Liu","year":"2011","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejpb.2015.05.001_b0310","doi-asserted-by":"crossref","first-page":"e7410","DOI":"10.1371\/journal.pone.0007410","article-title":"Ocular delivery of compacted DNA-nanoparticles does not elicit toxicity in the mouse retina","volume":"4","author":"Ding","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.ejpb.2015.05.001_b0315","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.arr.2009.06.002","article-title":"Regulatory role of HIF-1alpha in the pathogenesis of age-related macular degeneration (AMD)","volume":"8","author":"Arjamaa","year":"2009","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.ejpb.2015.05.001_b0320","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.exer.2006.01.016","article-title":"Oxygen-dependent diseases in the retina: role of hypoxia-inducible factors","volume":"83","author":"Arjamaa","year":"2006","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.ejpb.2015.05.001_b0325","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1001\/archopht.121.4.547","article-title":"Retinal oxygen: fundamental and clinical aspects","volume":"121","author":"Wangsa-Wirawan","year":"2003","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.ejpb.2015.05.001_b0330","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1167\/iovs.13-13255","article-title":"Retinal oximetry with a scanning laser ophthalmoscope","volume":"55","author":"Kristjansdottir","year":"2014","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejpb.2015.05.001_b0335","doi-asserted-by":"crossref","first-page":"6968","DOI":"10.1167\/iovs.13-12126","article-title":"In vivo retinal vascular oxygen tension imaging and fluorescein angiography in the mouse model of oxygen-induced retinopathy","volume":"54","author":"Mezu-Ndubuisi","year":"2013","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejpb.2015.05.001_b0340","doi-asserted-by":"crossref","first-page":"4766","DOI":"10.1167\/iovs.09-4710","article-title":"Retinal tissue oxygen tension imaging in the rat","volume":"51","author":"Shahidi","year":"2010","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejpb.2015.05.001_b0345","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1021\/bc500400z","article-title":"Molecular probes for imaging of hypoxia in the retina","volume":"25","author":"Evans","year":"2014","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejpb.2015.05.001_b0350","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1161\/01.RES.0000102937.50486.1B","article-title":"Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1","volume":"93","author":"Kelly","year":"2003","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejpb.2015.05.001_b0355","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.jconrel.2013.10.008","article-title":"Sustained delivery of a HIF-1 antagonist for ocular neovascularization","volume":"172","author":"Iwase","year":"2013","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"key":"10.1016\/j.ejpb.2015.05.001_b0360","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/gt.2009.158","article-title":"Inhibitory efficacy of hypoxia-inducible factor 1alpha short hairpin RNA plasmid DNA-loaded poly (D, l-lactide-co-glycolide) nanoparticles on choroidal neovascularization in a laser-induced rat model","volume":"17","author":"Zhang","year":"2010","journal-title":"Gene Ther."},{"key":"10.1016\/j.ejpb.2015.05.001_b0365","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1016\/j.bmcl.2010.05.009","article-title":"Carbonic anhydrase inhibitors","volume":"20","author":"Supuran","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejpb.2015.05.001_b0370","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1242\/jcs.079236","article-title":"A competitive hexapeptide inhibitor of annexin A2 prevents hypoxia-induced angiogenic events","volume":"124","author":"Valapala","year":"2011","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.ejpb.2015.05.001_b0375","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1016\/j.biomaterials.2013.11.022","article-title":"Hypoxia-responsive polymeric nanoparticles for tumor-targeted drug delivery","volume":"35","author":"Thambi","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2015.05.001_b0380","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1172\/JCI32430","article-title":"Senescence regulates macrophage activation and angiogenic fate at sites of tissue injury in mice","volume":"117","author":"Kelly","year":"2007","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejpb.2015.05.001_b0385","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jconrel.2010.11.029","article-title":"Suppression of phagocytic cells in retinal disorders using amphiphilic poly(gamma-glutamic acid) nanoparticles containing dexamethasone","volume":"151","author":"Ryu","year":"2011","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"key":"10.1016\/j.ejpb.2015.05.001_b0390","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.vaccine.2007.12.037","article-title":"Nanoparticles built by self-assembly of amphiphilic gamma-PGA can deliver antigens to antigen-presenting cells with high efficiency: a new tumor-vaccine carrier for eliciting effector T cells","volume":"26","author":"Yoshikawa","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.ejpb.2015.05.001_b0395","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.jconrel.2012.07.024","article-title":"Induction of potent CD8(+) T cell responses through the delivery of subunit protein vaccines to skin antigen-presenting cells using densely packed microprojection arrays","volume":"162","author":"Ng","year":"2012","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"key":"10.1016\/j.ejpb.2015.05.001_b0400","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/jmv.21029","article-title":"Poly(gamma-glutamic acid) nanoparticles as an efficient antigen delivery and adjuvant system: potential for an AIDS vaccine","volume":"80","author":"Wang","year":"2008","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.ejpb.2015.05.001_b0405","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.2337\/db08-1327","article-title":"Nanoparticle-mediated expression of an angiogenic inhibitor ameliorates ischemia-induced retinal neovascularization and diabetes-induced retinal vascular leakage","volume":"58","author":"Park","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.ejpb.2015.05.001_b0410","doi-asserted-by":"crossref","first-page":"6230","DOI":"10.1167\/iovs.10-6229","article-title":"Anti-inflammatory and antiangiogenic effects of nanoparticle-mediated delivery of a natural angiogenic inhibitor","volume":"52","author":"Jin","year":"2011","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejpb.2015.05.001_b0415","doi-asserted-by":"crossref","first-page":"14896","DOI":"10.1021\/ja507626y","article-title":"Cell protective, ABC triblock polymer-based thermoresponsive hydrogels with ROS-triggered degradation and drug release","volume":"136","author":"Gupta","year":"2014","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejpb.2015.05.001_b0420","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1016\/j.biomaterials.2014.01.026","article-title":"A porous tissue engineering scaffold selectively degraded by cell-generated reactive oxygen species","volume":"35","author":"Martin","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2015.05.001_b0425","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.jconrel.2012.07.042","article-title":"Poly(PS-b-DMA) micelles for reactive oxygen species triggered drug release","volume":"162","author":"Gupta","year":"2012","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"key":"10.1016\/j.ejpb.2015.05.001_b0430","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.nano.2008.05.003","article-title":"SOD activity of carboxyfullerenes predicts their neuroprotective efficacy: a structure-activity study","volume":"4","author":"Ali","year":"2008","journal-title":"Nanomedicine"},{"key":"10.1016\/j.ejpb.2015.05.001_b0435","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.neurobiolaging.2006.09.014","article-title":"A carboxyfullerene SOD mimetic improves cognition and extends the lifespan of mice","volume":"29","author":"Quick","year":"2008","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.ejpb.2015.05.001_b0440","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.freeradbiomed.2004.07.002","article-title":"A biologically effective fullerene (C60) derivative with superoxide dismutase mimetic properties","volume":"37","author":"Ali","year":"2004","journal-title":"Free Radical Biol. Med."},{"key":"10.1016\/j.ejpb.2015.05.001_b0445","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/978-1-4614-3209-8_103","article-title":"Nanoceria as bona fide catalytic antioxidants in medicine: what we know and what we want to know","volume":"801","author":"Wong","year":"2014","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.ejpb.2015.05.001_b0450","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.biomaterials.2013.10.022","article-title":"Sustained inhibition of neovascularization in vldlr\u2013\/\u2013 mice following intravitreal injection of cerium oxide nanoparticles and the role of the ASK1-P38\/JNK-NF-kappaB pathway","volume":"35","author":"Cai","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2015.05.001_b0455","doi-asserted-by":"crossref","first-page":"e58431","DOI":"10.1371\/journal.pone.0058431","article-title":"Catalytic nanoceria are preferentially retained in the rat retina and are not cytotoxic after intravitreal injection","volume":"8","author":"Wong","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejpb.2015.05.001_b0460","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.exer.2013.08.003","article-title":"Nanoceria inhibit expression of genes associated with inflammation and angiogenesis in the retina of Vldlr null mice","volume":"116","author":"Kyosseva","year":"2013","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.ejpb.2015.05.001_b0465","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.2217\/nnm.13.133","article-title":"Cerium oxide nanoparticles: applications and prospects in nanomedicine","volume":"8","author":"Das","year":"2013","journal-title":"Nanomedicine"},{"key":"10.1016\/j.ejpb.2015.05.001_b0470","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/nnano.2006.91","article-title":"Rare earth nanoparticles prevent retinal degeneration induced by intracellular peroxides","volume":"1","author":"Chen","year":"2006","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.ejpb.2015.05.001_b0475","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0058431","article-title":"Correction: catalytic nanoceria are preferentially retained in the rat retina and are not cytotoxic after intravitreal injection","volume":"8","author":"Wong","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejpb.2015.05.001_b0480","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1007\/s11095-013-1289-8","article-title":"Specific binding, uptake, and transport of ICAM-1-targeted nanocarriers across endothelial and subendothelial cell components of the blood-brain barrier","volume":"31","author":"Hsu","year":"2014","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2015.05.001_b0485","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1007\/s11095-005-7247-3","article-title":"Immunoliposomes directed toward VCAM-1 interact specifically with activated endothelial cells \u2013 a potential tool for specific drug delivery","volume":"22","author":"Voinea","year":"2005","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2015.05.001_b0490","doi-asserted-by":"crossref","first-page":"26","DOI":"10.4103\/0974-9233.106384","article-title":"Nanotechnology approaches for ocular drug delivery","volume":"20","author":"Xu","year":"2013","journal-title":"Middle East Afr. J. Ophthalmol."},{"key":"10.1016\/j.ejpb.2015.05.001_b0495","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1089\/jop.2012.0232","article-title":"Dendrimer nanoparticles for ocular drug delivery","volume":"29","author":"Kambhampati","year":"2013","journal-title":"J. Ocul. Pharmacol. Ther. Off. J. Assoc. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2015.05.001_b0500","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003162","article-title":"Dendrimer-based postnatal therapy for neuroinflammation and cerebral palsy in a rabbit model","volume":"4","author":"Kannan","year":"2012","journal-title":"Sci. Translational Med."},{"key":"10.1016\/j.ejpb.2015.05.001_b0505","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.biomaterials.2011.10.010","article-title":"Dendrimer-based targeted intravitreal therapy for sustained attenuation of neuroinflammation in retinal degeneration","volume":"33","author":"Iezzi","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2015.05.001_b0510","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.2217\/nnm.10.89","article-title":"Intrinsic targeting of inflammatory cells in the brain by polyamidoamine dendrimers upon subarachnoid administration","volume":"5","author":"Dai","year":"2010","journal-title":"Nanomedicine"},{"key":"10.1016\/j.ejpb.2015.05.001_b0515","article-title":"Biocompatible mannosylated endosomal-escape nanoparticles enhance selective delivery of short nucleotide sequences to tumor associated macrophages","author":"Ortega","year":"2014","journal-title":"Nanoscale"},{"key":"10.1016\/j.ejpb.2015.05.001_b0520","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1021\/mp300434e","article-title":"Macrophage-specific RNA interference targeting via \u201cclick\u201d, mannosylated polymeric micelles","volume":"10","author":"Yu","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2015.05.001_b0525","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2147\/IJN.S28531","article-title":"Size- and charge-dependent non-specific uptake of PEGylated nanoparticles by macrophages","volume":"7","author":"Yu","year":"2012","journal-title":"Int. J. Nanomed."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641115002192?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641115002192?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,25]],"date-time":"2019-08-25T19:55:03Z","timestamp":1566762903000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641115002192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":105,"alternative-id":["S0939641115002192"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2015.05.001","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nanoengineering of therapeutics for retinal vascular disease","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2015.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}